Human B-cell antigen receptor specific for Enterovirus A71 epitopes (EV-A71-specific BCR)

Human B-cell antigen receptors (BCRs) specific for Enterovirus A71 (EV-A71) epitopes are specialized transmembrane proteins on B lymphocytes that recognize specific molecular patterns on the EV-A71 capsid, particularly the VP1, VP2, and VP3 proteins [1][4]. These receptors are central to the adaptive immune response, as their engagement by viral antigens triggers B-cell proliferation and the production of neutralizing antibodies that prevent viral entry into host cells [2][3]. EV-A71 is a major causative agent of hand, foot, and mouth disease (HFMD), which can progress to severe neurological conditions like brainstem encephalitis and pulmonary edema in young children [1][5]. In therapeutic development, these BCRs are the primary targets for inactivated vaccines, which aim to prime the immune system to recognize these specific epitopes upon subsequent exposure [3][6]. Additionally, the study of these receptors allows for the isolation of high-potency monoclonal antibodies that can be used as passive immunotherapy for severe cases of EV-A71 infection [4][7]. Sources: [1] WHO Hand, Foot and Mouth Disease Fact Sheet; [2] Janeway's Immunobiology, 9th Ed; [3] Mao et al. (2016) Vaccine; [4] Huang et al. (2015) Nature Communications; [5] Solomon et al. (2010) Lancet Infectious Diseases; [6] Yi et al. (2017) Clin Exp Vaccine Res; [7] Lim et al. (2012) Journal of Virology.

Other names

EV-A71-specific B-cell receptorAnti-EV-A71 BCREnterovirus 71-specific B-cell antigen receptorEV-A71-specific immunoglobulin receptor

Vaccine-mediated stimulation of specific B-cell antigen receptors to induce clonal expansion and the secretion of neutralizing antibodies that bind to viral capsid proteins, preventing viral attachment and entry into host cells.